Multiple studies have validated RAF as the key mediator in mutant RAS-driven cancer growth and progression.427–429 However, current RAF inhibitors approved for treating BRAFV600E mutant melanoma are not effective in targeting RAS mutant cancer due to their unique pharmacologic features. This evidence concerns the gene RAF1 and melanoma.